Does Semaglutide Cause Muscle Loss?

Short answer: some of the weight you lose on semaglutide is lean tissue rather than fat. That is real, it is measurable, and it is also true of nearly every method of losing a lot of weight. The interesting questions are how much, whether it matters, and what changes it.

This is not medical advice. It describes what published studies and the FDA label report.

What do the studies actually measure?

Start here, because it explains most of the confusion.

The standard tool is a DXA scan, which divides the body into fat mass, lean body mass and bone. Lean body mass is not the same as muscle. It includes skeletal muscle, but also organs, connective tissue and water. When you lose weight fast, you lose glycogen and the water stored with it, and that shows up as lean mass loss on a scan without any muscle fiber disappearing.

Some studies use bioelectrical impedance instead, which is cheaper, less precise and sensitive to hydration. Others report lean mass in kilograms, others as a percentage of weight lost, others as a proportion of total body mass. Those are three different numbers, and headlines swap between them freely.

That is why you will see “45% of weight lost was muscle” and “lean mass proportion actually increased” attributed to the same trial. Both can be technically defensible descriptions of the same data.

What did the semaglutide trials find?

STEP 1 DXA substudy. In the main 68-week trial of Wegovy 2.4 mg, 140 participants at nine sites had DXA scans at screening and week 68, 95 on semaglutide and 45 on placebo. Mean baseline weight was 98.4 kg and mean BMI 34.8. Body weight changed by -15.0% with semaglutide versus -3.6% with placebo [2].

At baseline, the semaglutide group was 43.4% fat and 53.9% lean by proportion of total body mass. By week 68 both absolute fat mass and absolute lean mass had fallen, but the proportion of the body made up of lean mass had risen, because fat fell faster [2]. The investigators labeled the analysis exploratory and did not correct for multiple comparisons, so it should be read as descriptive.

COURAGE phase 2. Interim results from a trial testing whether adding another agent preserves lean mass reported that roughly 35% of semaglutide-induced weight loss in the semaglutide-only arm was lean mass [1]. This is the figure most often quoted as the headline number.

SEMALEAN, 2026. A prospective study of 115 patients with obesity, followed by DXA at baseline, 7 months and 12 months. Total fat mass fell 14% at 7 months and 18% at 12 months. Lean mass fell about 3 kg by 7 months and then stabilized, while fat continued to come off [3].

That last finding is the most practically useful thing in this literature. It suggests the lean mass loss is front-loaded, concentrated in the rapid early phase, and does not simply continue in a straight line.

What does the FDA label say?

Not much, which is itself informative. Muscle loss is not listed as an adverse reaction on any semaglutide label.

The Clinical Pharmacology section of the Wegovy label states that semaglutide lowers body weight with greater fat mass loss than lean mass loss [4]. That is a claim about the ratio, not a denial that lean mass falls.

There is one related labeled finding worth knowing. In the Wegovy cardiovascular outcomes trial, more hip and pelvis fractures were reported on semaglutide than placebo among women, at 1% (24 of 2,448) versus 0.2% (5 of 2,424), and among people aged 75 and older, at 2.4% (17 of 703) versus 0.6% (4 of 663) [4]. The label does not attribute this to muscle loss, and fracture risk after weight loss has multiple possible causes including bone density changes and altered balance. But it is the labeled signal that is closest to the functional concern people have.

Is this specific to semaglutide, or does it happen with any weight loss?

Any large weight loss takes lean tissue with it. Reviews of the topic consistently make this point: the body does not selectively burn fat when it is in a calorie deficit [6].

A reasonable comparison point often cited is bariatric surgery, which also produces substantial lean mass loss. Reported figures for GLP-1 drugs fall in a broadly similar range to what is seen with equivalent weight loss by other means.

There is an open scientific question about whether GLP-1 drugs do anything extra to muscle beyond the calorie deficit. Some preclinical work has raised questions about direct effects on skeletal muscle, and reviews describe the effects on muscle mass, quality, strength and physical performance in older adults as incompletely understood [6]. That is an honest “we don’t fully know yet,” not a finding.

Does muscle loss actually matter?

It depends on who you are and how much you had to start with.

Arguments that it matters less than headlines suggest. People with obesity typically carry more absolute lean mass than people at lower weights, because supporting more body mass builds muscle. Losing some of it while losing the load it was carrying is not obviously harmful. And the proportional data from STEP 1 shows body composition improving, not worsening, on the metric that describes what fraction of you is lean [2].

Arguments that it matters more. Muscle is metabolically active tissue. It is where most glucose disposal happens, which is relevant for people with type 2 diabetes. Muscle mass is tied to strength, mobility, balance and independence, especially with age. And for older adults already losing muscle with age, an additional loss stacks onto an existing decline. Reviews of GLP-1 therapy in older adults emphasize that preventing muscle loss should be a primary consideration, given that sarcopenia is associated with increased morbidity and mortality [6].

The population where this matters most is fairly specific: older adults, people with existing low muscle mass or frailty, and people losing weight very fast with little protein and no resistance training.

What actually reduces muscle loss?

This is where the evidence is more encouraging than the headlines.

Resistance training plus protein. A prospective 6-month study of 200 adults with overweight or obesity gave education on resistance training and protein intake at the time they started semaglutide or tirzepatide. At 6 months, bioelectrical impedance showed they had lost about 13% of body weight but only about 3% of muscle mass [5]. That is a markedly better ratio than the figures from trials where participants received no such counseling.

The study author’s framing is worth quoting because it captures the clinical position: these medications work best under the care of experienced providers who can offer guidance on physical activity, nutrition and body composition, and used that way they can optimize health while preserving muscle mass [5].

Protein intake. Published clinical guidance for adults in active weight loss commonly lands around 1.2 to 1.6 grams of protein per kilogram of body weight per day, with older adults and people training intensively sometimes advised toward 1.6 to 2.0 g/kg [5][6]. For a 90 kg person that is roughly 110 to 145 grams a day. Those are figures reported in the literature, not a recommendation for you; a healthcare provider or registered dietitian should set an individual target.

The specific difficulty on a GLP-1 drug is that appetite suppression is the point of the medication. When someone eats far less overall, protein is often the first macronutrient to fall short, because it is the least appealing thing to eat when you feel full. That is a real, practical obstacle, not a motivation problem.

Pace of weight loss. Faster loss gives the body less time to adapt. The SEMALEAN pattern, lean mass falling early then stabilizing, is consistent with the idea that the rapid initial phase drives most of the lean loss [3].

Body composition monitoring. DXA or bioelectrical impedance measurement at baseline and periodically tells you what the scale cannot: whether what you are losing is what you wanted to lose. This is increasingly part of how clinicians manage GLP-1 therapy.

How would you know if you were losing too much?

There is no consumer test for this, and the honest answer is that the scale will not tell you. Things people and clinicians watch for:

• Strength dropping noticeably: lifting, carrying, stairs, getting up from a chair.
• Fatigue and weakness out of proportion to the weight lost.
• For older adults, changes in balance, gait speed or grip strength, which are the measures geriatricians use.
• Protein intake that has quietly collapsed because eating became difficult.

Any of these is worth raising with a healthcare provider rather than pushing through.

What about drugs designed to preserve muscle?

Several companies are testing agents intended to be added to a GLP-1 drug specifically to preserve lean mass. The COURAGE phase 2 trial, whose interim results produced the 35% figure quoted above, is one such program. It pairs semaglutide with trevogrumab, an anti-myostatin antibody, with or without garetosmab. Adding those antibodies spared roughly 50% to 80% of the lean mass lost on semaglutide alone [1].

The furthest-along published result is the BELIEVE phase 2 trial of bimagrumab, an antibody that blocks activin type II receptors, reported in Nature Medicine in March 2026. Over 72 weeks, people on semaglutide alone lost about 7.4% of their lean mass; those on the bimagrumab and semaglutide combination lost about 2.9%, while losing more total weight and substantially more fat [7].

These are genuinely promising results, and they are also phase 2 results. None of these agents is FDA-approved for this or any other use, none has long-term safety data, and none is available outside a trial. There is nothing here to act on today beyond protein and resistance training.

Clinicians quoted on this topic have suggested that adjunctive medications for muscle preservation will likely be needed mainly for patients with true sarcopenia who cannot tolerate any muscle loss during weight loss, with broader use depending on how strong the safety profile turns out to be [5].

The short version

• Some of the weight lost on semaglutide is lean tissue. Estimates cluster around a third of total weight lost in trials where participants got no specific muscle-preservation support [1].
• Lean mass on a scan is not the same as skeletal muscle, and much of the early loss is water and glycogen.
• In the STEP 1 DXA substudy, the proportion of the body made of lean mass went up, because fat fell faster [2]. In a 2026 DXA study, lean mass fell early then stabilized while fat kept falling [3].
• Muscle loss is not a labeled adverse reaction. The Wegovy label does report more hip and pelvis fractures in women and in people 75 and older in the cardiovascular outcomes trial [4].
• Resistance training and adequate protein appear to change the picture substantially: about 13% body weight lost with only about 3% muscle lost in a cohort that received that counseling [5].
• Older adults and people with existing low muscle mass have the most to lose and should discuss it with a healthcare provider before and during treatment.

Sources

1. Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide-Induced Weight Loss by Preserving Lean Mass — Regeneron Pharmaceuticals
2. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study — Wilding JPH et al.
3. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study — Diabetes, Obesity and Metabolism, 2026
4. WEGOVY (semaglutide) Prescribing Information — U.S. Food and Drug Administration, revised June 2026
5. Resistance Training + Protein May Lower GLP-1 RA Muscle Loss — Medscape, 2025
6. Muscle loss and GLP-1R agonists use — review, 2026
7. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial — Nature Medicine, March 30, 2026